USFDA approves Carvykti for patients with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy
Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. “With this […]